AI-driven biomarkers for antibody-drug conjugates
- Author(s)
- Loi, S; Salgado, R;
- Details
- Publication Year 2025-06-09,Volume 43,Issue #6,Page 1000-1002
- Journal Title
- Cancer Cell
- Publication Type
- Commentary
- Abstract
- Currently, no biomarker reliably predicts the efficacy of antibody-drug conjugates (ADCs). In this issue of Cancer Cell, Ma et al. present a predictive model for HER2-targeting ADC efficacy, incorporating immune-system components, hormone receptor status, clinical staging, and HER2+ cell proportion.
- Publisher
- Cell Press
- Keywords
- Humans; *Immunoconjugates/therapeutic use/pharmacology; *Biomarkers, Tumor/metabolism; Receptor, ErbB-2/metabolism/antagonists & inhibitors; *Neoplasms/drug therapy
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.1016/j.ccell.2025.03.020
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-05-13 07:45:05
Last Modified: 2025-07-31 02:10:26